Diabetes Medical Schools Pharmacy Management 
Pharmacy Times
JULY 23, 2025
Semaglutide shows superior cardiovascular and renal benefits, with FDA-approved indications for reducing major adverse cardiovascular events and chronic kidney disease progression.
Pharmacy Times
JUNE 19, 2025
Perioperative treatment should be tailored today based on individual clinical and genomic features for patients with EGFR - and ALK -type [NSCLC],” concluded Biagio Ricciuti, MD, PhD, from the Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School.
Expert insights. Personalized for you.
Let's personalize your content